Skip to main content

Table 2 Clinical information (n = 25)

From: Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

Characteristic Value
Duration of ICI therapy, days, median (IQR) 54 (1–525)
Number of ICI infusions at time of onset, median (IQR) 4 (1–21)
Time from ICI initiation to onset, months, median (IQR) 6 (0.1–31)
Duration of symptoms, days, median (IQR) 5 (3–12)
Peak biochemistry values, median (IQR)
 White blood cell count, cells/L 7.8 (0.7–33.0)
 Total bilirubin, mg/dL 1.4 (0.4–36.1)
 Direct bilirubin, mg/dL 0.9 (0.2–33.4)
 Alkaline phosphatase, IU/L 167 (34–1281)
 ALT, IU/L 55 (12–364)
 AST, IU/L 47 (16–434)
Cholecystitis clinical presentation, n (%)
 Abdominal pain 18 (72)
 Nausea and vomiting 11 (44)
 Diarrhea 3 (12)
 Fever 5 (20)
Positive infectious workup at time of onset, n (%) 2 (8)
Histopathologic examination performed, n (%) 4 (16)
  1. ICI immune checkpoint inhibitor, IQR interquartile range, ALT alanine aminotransferase, AST aspartate aminotransferase